2008

1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

   Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

   HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313